Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05276310 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05276310 · ClinicalTrials.gov record · last posted 2026-04-24

A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy

StatusRecruiting
PhasePhase 1
Started2022-06-02
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is an Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients with Advanced Cancer Failed to Standard Therapy

Amendment record 7 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 7 times since 2022-03-02; most recent amendment 2026-04-21. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2022-06-02
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT05276310
Lead Sponsor ImmuneOncia Therapeutics Inc.
Conditions Advanced Cancer
Enrollment 62 participants
Start Date 2022-06-02
Primary Completion 2027-12-17 (estimated)
Study Completion 2029-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-24